Strategic Alliances
We believe that our antisense technology is broadly applicable for the potential development of pharmaceutical products in many therapeutic areas. To exploit our core technology as fully as possible, our strategy is to enter into collaborative development agreements with strategic partners or major pharmaceutical companies for specific molecular targets or selected disease indications for our NeuGene antisense technology.
We currently have strategic alliances with the following companies and institutions:
- Cook Group
- for vascular diseases using NeuGene drugs with devices
- DepoMed, Inc.
- for the development of oral delivery of antisense
- U.S. Department of Defense
- for Ebola, Marburg and Dengue viruses; Ricin and Anthrax toxins
- USAMRIID
- for BSL–4 threats, including avian influenza, H5N1
- Eleos, Inc.
- to treat cancer with p53-related drugs
- Imperial College, London
- for clinical trials in muscular dystrophy